Effect of sulfated glycosaminoglycans on tumor invasion and metastasis

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 4, 2011, Pages 1541-1551

  Kozlowski, Eliene O ^a   Pavao, Mauro S G ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Epithelial To Mesenchymal Transition; Glycosaminoglycans; Hematogeneous Metastasis; Metastasis; Review

Indexed keywords

ANTIMETASTATIC AGENT; DERMATAN SULFATE DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; GLYCOSAMINOGLYCAN POLYSULFATE; GLYPICAN 3; HEPARAN SULFATE; HEPARANASE; HEPARIN DERIVATIVE; HERBACEOUS AGENT; L SELECTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE CELL ADHESION MOLECULE; PADGEM PROTEIN; PROTEIN KINASE B; PROTEOHEPARAN SULFATE; SCATTER FACTOR; SIALYL LEWIS X ANTIGEN; SULFATASE; SYNDECAN; SYNDECAN 1; UVOMORULIN; VIMENTIN; WNT PROTEIN; A73025; HEPARIN;

APOPTOSIS; BASEMENT MEMBRANE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHORDATA; DOWN REGULATION; EFFECTOR CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE SILENCING; GLYCOSYLATION; HOLOTHURIA; HOLOTHURIA GRISEA; IC 50; INTRACELLULAR SIGNALING; LIGAND BINDING; MESOTHELIOMA; METASTASIS; METASTASIS INHIBITION; MOLLUSC; MYELOMA CELL; NONHUMAN; PHALLUSIA NIGRA; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SEA CUCUMBER; STYELA PLICATA; TUMOR ESCAPE; TUMOR INVASION; UPREGULATION; ARTICLE; BIOLOGICAL MODEL; CANCER INVASION; DRUG EFFECT; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; P-SELECTIN;

EID: 80052424869     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. S. Mizuguchi, T. Uyama, H. Kitagawa, K. H. Nomura, K. Dejima, K. Gengyo-Ando, S. Mitani, K. Sugahara and K. Nomura: Chondroitin proteoglycans are involved in cell division of Caenorhabditis elegans. Nature, 423(6938), 443-8 (2003)
2. G. K. Dhoot, M. K. Gustafsson, X. Ai, W. Sun, D. M. Standiford and C. P. Emerson, Jr.: Regulation of Wntsignaling and embryo patterning by an extracellular sulfatase. Science, 293(5535), 1663-6 (2001)
3. U. Hacker, K. Nybakken and N. Perrimon: Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol, 6(7), 530-41 (2005)
4. C. H. Chau, D. K. Shum, H. Li, J. Pei, Y. Y. Lui, L. Wirthlin, Y. S. Chan and X. M. Xu: Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded guidance channels after spinal cord injury. FASEB J, 18(1), 194-6 (2004)
5. E. J. Bradbury, L. D. Moon, R. J. Popat, V. R. King, G. S. Bennett, P. N. Patel, J. W. Fawcett and S. B. McMahon: Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature, 416(6881), 636-40 (2002)
6. D. Carulli, T. Laabs, H. M. Geller and J. W. Fawcett: Chondroitin sulfate proteoglycans in neural development and regeneration. Curr Opin Neurobiol, 15(1), 116-20 (2005)
7. I. Vlodavsky, O. Goldshmidt, E. Zcharia, R. Atzmon, Z. Rangini-Guatta, M. Elkin, T. Peretz and Y. Friedmann: Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol, 12(2), 121-9 (2002)
8. B. Casu, M. Guerrini, A. Naggi, M. Perez, G. Torri, D. Ribatti, P. Carminati, G. Giannini, S. Penco, C. Pisano, M. Belleri, M. Rusnati and M. Presta: Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. Biochemistry, 41(33), 10519-28 (2002)
9. R. V. Iozzo: Basement membrane proteoglycans: from cellar to ceiling. Nat Rev Mol Cell Biol, 6(8), 646-56 (2005)
10. J. Liu, Z. Shriver, R. M. Pope, S. C. Thorp, M. B. Duncan, R. J. Copeland, C. S. Raska, K. Yoshida, R. J. Eisenberg, G. Cohen, R. J. Linhardt and R. Sasisekharan: Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem, 277(36), 33456-67 (2002)
11. K. Mardberg, E. Trybala, F. Tufaro and T. Bergstrom: Herpes simplex virus type 1 glycoprotein C is necessary for efficient infection of chondroitin sulfate-expressing gro2C cells. J Gen Virol, 83(Pt 2), 291-300 (2002)
12. D. M. Tollefsen: Vascular dermatan sulfate and heparin cofactor II. Prog Mol Biol Transl Sci, 93, 351-72 (2010)
13. M. S. Pavao, P. A. Mourao, B. Mulloy and D. M. Tollefsen: A unique dermatan sulfate-like glycosaminoglycan from ascidian. Its structure and the effect of its unusual sulfation pattern on anticoagulant activity. J Biol Chem, 270(52), 31027-36 (1995)
14. U. Lindahl, M. Kusche, K. Lidholt and L. G. Oscarsson: Biosynthesis of heparin and heparan sulfate. Ann N Y Acad Sci, 556, 36-50 (1989)
15. D. L. Rabenstein: Heparin and heparan sulfate: structure and function. Nat Prod Rep, 19(3), 312-31 (2002)
16. N. M. Melo-Filho, C. L. Belmiro, R. G. Goncalves, C. M. Takiya, M. Leite, Jr., M. S. Pavao and P. A. Mourao: Fucosylated chondroitin sulfate attenuates renal fibrosis in animals submitted to unilateral ureteral obstruction: a P-selectin-mediated event? Am J Physiol Renal Physiol, 299(6), F1299-307 (2010)
17. C. L. Belmiro, M. T. Castelo-Branco, L. M. Melim, A. Schanaider, C. Elia, K. Madi, M. S. Pavao and H. S. de Souza: Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem, 284(17), 11267-78 (2009)
18. L. Borsig, L. Wang, M. C. Cavalcante, L. Cardilo- Reis, P. L. Ferreira, P. A. Mourao, J. D. Esko and M. S. Pavao: Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem, 282(20), 14984-91 (2007)
19. M. Belting, L. Borsig, M. M. Fuster, J. R. Brown, L. Persson, L. A. Fransson and J. D. Esko: Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci U S A, 99(1), 371-6 (2002)
20. L. Borsig: Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost, 33(5), 540-6 (2007)
21. L. Borsig, R. Wong, J. Feramisco, D. R. Nadeau, N. M. Varki and A. Varki: Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A, 98(6), 3352-7 (2001)
22. N. Hostettler, A. Naggi, G. Torri, R. Ishai-Michaeli, B. Casu, I. Vlodavsky and L. Borsig: P-selectin- and heparanase-dependent antimetastatic activity of nonanticoagulant heparins. FASEB J, 21(13), 3562-72 (2007)
23. H. Laubli and L. Borsig: Heparins attenuate cancer metastasis: are selectins the link? Cancer Invest, 27(5), 474-81 (2009)
24. D. Liu, Z. Shriver, Y. Qi, G. Venkataraman and R. Sasisekharan: Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin Thromb Hemost, 28(1), 67-78 (2002)
25. J. M. Trowbridge and R. L. Gallo: Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology, 12(9), 117R-25R (2002)
26. S. A. Mousa and L. J. Petersen: Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost, 102(2), 258-67 (2009)
27. M. Presta, D. Leali, H. Stabile, R. Ronca, M. Camozzi, L. Coco, E. Moroni, S. Liekens and M. Rusnati: Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des, 9(7), 553-66 (2003)
28. S. Miyamoto, H. Yagi, F. Yotsumoto, S. Horiuchi, T. Yoshizato, T. Kawarabayashi, M. Kuroki and E. Mekada: New approach to cancer therapy: heparin bindingepidermal growth factor-like growth factor as a novel targeting molecule. Anticancer Res, 27(6A), 3713-21 (2007)
29. G. M. Smith and C. Strunz: Growth factor and cytokine regulation of chondroitin sulfate proteoglycans by astrocytes. Glia, 52(3), 209-18 (2005)
30. J. Tapon-Bretaudiere, D. Chabut, M. Zierer, S. Matou, D. Helley, A. Bros, P. A. Mourao and A. M. Fischer: A fucosylated chondroitin sulfate from echinoderm modulates in vitro fibroblast growth factor 2-dependent angiogenesis. Mol Cancer Res, 1(2), 96-102 (2002)
31. K. R. Taylor and R. L. Gallo: Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J, 20(1), 9-22 (2006)
32. D. F. Zech, S. Grond, J. Lynch, D. Hertel and K. A. Lehmann: Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain, 63(1), 65-76 (1995)
33. L. Weiss, E. Grundmann, J. Torhorst, F. Hartveit, I. Moberg, M. Eder, C. M. Fenoglio-Preiser, J. Napier, C. H. Horne, M. J. Lopez and et al.: Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol, 150(3), 195-203 (1986)
34. M. L. Butler, R. L. Van Heertum and S. K. Teplick: Metastatic malignant melanoma of the esophagus: a case report. Gastroenterology, 69(6), 1334-7 (1975)
35. E. Mayhew and D. Glaves: Quantitation of tumorigenic disseminating and arrested cancer cells. Br J Cancer, 50(2), 159-66 (1984)
36. C. Mundhenke, K. Meyer, S. Drew and A. Friedl: Heparan sulfateproteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol, 160(1), 185-94 (2002)
37. K. Zen, D. Q. Liu, L. M. Li, C. X. Chen, Y. L. Guo, B. Ha, X. Chen, C. Y. Zhang and Y. Liu: The heparan sulfate proteoglycan form of epithelial CD44v3 serves as a CD11b/CD18 counter-receptor during polymorphonuclear leukocyte transepithelial migration. J Biol Chem, 284(6), 3768-76 (2009)
38. B. U. Pauli, D. E. Schwartz, E. J. Thonar and K. E. Kuettner: Tumor invasion and host extracellular matrix. Cancer Metastasis Rev, 2(2), 129-52 (1983)
39. E. Oleszak: Inhibition of mitogenic activity of PDGF, EGF, and FGF by interferon-gamma. Exp Cell Res, 179(2), 575-80 (1988)
40. S. Higgins, S. H. Wong, M. Richner, C. L. Rowe, D. F. Newgreen, G. A. Werther and V. C. Russo: Fibroblast growth factor 2 reactivates G1 checkpoint in SK-N-MC cells via regulation of p21, inhibitor of differentiation genes (Id1-3), and epithelium-mesenchyme transition-like events. Endocrinology, 150(9), 4044-55 (2009)
41. Y. C. Yeh, E. R. Burns, J. Yeh and H. W. Yeh: Synergistic effects of endothelin-1 (ET-1) and transforming growth factor alpha (TGF-alpha) or epidermal growth factor (EGF) on DNA replication and G1 to S phase transition. Biosci Rep, 11(3), 171-80 (1991)
42. D. R. Clemmons and L. I. Gardner: A factor contained in plasma is required for IGF binding protein-1 to potentiate the effect of IGF-I on smooth muscle cell DNA synthesis. J Cell Physiol, 145(1), 129-35 (1990)
43. K. V. Ramana, R. Tammali and S. K. Srivastava: Inhibition of aldose reductase prevents growth factorinduced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells. Mol Cancer Ther, 9(4), 813-24 (2010)
44. C. S. Bryant, S. Kumar, S. Chamala, J. Shah, J. Pal, M. Haider, S. Seward, A. M. Qazi, R. Morris, A. Semaan, M. A. Shammas, C. Steffes, R. B. Potti, M. Prasad, D. W. Weaver and R. B. Batchu: Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Mol Cancer, 9, 47 (2010)
45. S. Elangovan, T. C. Hsieh and J. M. Wu: Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor geneproduct. Anticancer Res, 28(5A), 2641-7 (2008)
46. A. Mauviel, M. Santra, Y. Q. Chen, J. Uitto and R. V. Iozzo: Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-alpha. J Biol Chem, 270(19), 11692-700 (1995)
47. T. Scholzen, M. Solursh, S. Suzuki, R. Reiter, J. L. Morgan, A. M. Buchberg, L. D. Siracusa and R. V. Iozzo: The murine decorin. Complete cDNA cloning, genomic organization, chromosomal assignment, and expression during organogenesis and tissue differentiation. J Biol Chem, 269(45), 28270-81 (1994)
48. A. De Luca, M. Santra, A. Baldi, A. Giordano and R. V. Iozzo: Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclindependent kinases. J Biol Chem, 271(31), 18961-5 (1996)
49. R. V. Iozzo, D. K. Moscatello, D. J. McQuillan and I. Eichstetter: Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem, 274(8), 4489-92 (1999)
50. M. Santra, I. Eichstetter and R. V. Iozzo: An antioncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem, 275(45), 35153-61 (2000)
51. G. Csordas, M. Santra, C. C. Reed, I. Eichstetter, D. J. McQuillan, D. Gross, M. A. Nugent, G. Hajnoczky and R. V. Iozzo: Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem, 275(42), 32879-87 (2000)
52. A. Hildebrand, M. Romaris, L. M. Rasmussen, D. Heinegard, D. R. Twardzik, W. A. Border and E. Ruoslahti: Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J, 302 ( Pt 2), 527-34 (1994)
53. S. F. Penc, B. Pomahac, T. Winkler, R. A. Dorschner, E. Eriksson, M. Herndon and R. L. Gallo: Dermatan sulfate released after injury is a potent promoter of fibroblast growth factor-2 function. J Biol Chem, 273(43), 28116-21 (1998)
54. J. Yang, M. A. Price, C. L. Neudauer, C. Wilson, S. Ferrone, H. Xia, J. Iida, M. A. Simpson and J. B. McCarthy: Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol, 165(6), 881-91 (2004)
55. R. Sasisekharan, Z. Shriver, G. Venkataraman and U. Narayanasami: Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer, 2(7), 521-8 (2002)
56. V. P. Eswarakumar, I. Lax and J. Schlessinger: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev, 16(2), 139-49 (2005)
57. A. Mansukhani, P. Dell'Era, D. Moscatelli, S. Kornbluth, H. Hanafusa and C. Basilico: Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin. Proc Natl Acad Sci U S A, 89(8), 3305-9 (1992)
58. A. Yayon, M. Klagsbrun, J. D. Esko, P. Leder and D. M. Ornitz: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell, 64(4), 841-8 (1991)
59. L. Pellegrini: Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol, 11(5), 629-34 (2001)
60. Y. Zhang, J. Li, C. Partovian, F. W. Sellke and M. Simons: Syndecan-4 modulates basic fibroblast growth factor 2 signaling in vivo. Am J Physiol Heart Circ Physiol, 284(6), H2078-82 (2003)
61. L. Borsig: Heparin as an inhibitor of cancer progression. Prog Mol Biol Transl Sci, 93, 335-49 (2010)
62. J. L. Stevenson, A. Varki and L. Borsig: Heparin attenuates metastasis mainly due to inhibition of P- and Lselectin, but non-anticoagulant heparins can have additional effects. Thromb Res, 120 Suppl 2, S107-11 (2007)
63. Y. Zhang, J. C. Rassa, M. E. deObaldia, L. M. Albritton and S. R. Ross: Identification of the receptor binding domain of the mouse mammary tumor virus envelope protein. J Virol, 77(19), 10468-78 (2003)
64. A. Ashkenazi: Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer, 2(6), 420-30 (2002)
65. D. Hanahan and R. A. Weinberg: The hallmarks of cancer. Cell, 100(1), 57-70 (2000)
66. X. Z. Wu and D. Chen: Effects of sulfated polysaccharides on tumour biology. West Indian Med J, 55(4), 270-3 (2006)
67. G. M. Campo, A. Avenoso, S. Campo, A. D'Ascola, P. Traina, D. Sama and A. Calatroni: Glycosaminoglycans modulate inflammation and apoptosis in LPS-treated chondrocytes. J Cell Biochem, 106(1), 83-92 (2009)
68. H. Lin, R. Huber, D. Schlessinger and P. J. Morin: Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res, 59(4), 807-10 (1999)
69. S. S. Murthy, T. Shen, A. De Rienzo, W. C. Lee, P. C. Ferriola, S. C. Jhanwar, B. T. Mossman, J. Filmus and J. R. Testa: Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene, 19(3), 410-6 (2000)
70. Y. Y. Xiang, V. Ladeda and J. Filmus: Glypican-3 expression is silenced in human breast cancer. Oncogene, 20(50), 7408-12 (2001)
71. C. Buchanan, I. Stigliano, H. M. Garay-Malpartida, L. Rodrigues Gomes, L. Puricelli, M. C. Sogayar, E. Bal de Kier Joffe and M. G. Peters: Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways. Breast Cancer Res Treat, 119(3), 559-74 (2010)
72. A. D. Gonzalez, M. Kaya, W. Shi, H. Song, J. R. Testa, L. Z. Penn and J. Filmus: OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol, 141(6), 1407-14 (1998)
73. J. P. Lai, D. S. Sandhu, C. Yu, C. D. Moser, C. Hu, A. M. Shire, I. Aderca, L. M. Murphy, A. A. Adjei, S. Sanderson and L. R. Roberts: Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver Int, 30(10), 1522-8 (2010)
74. M. Mali, H. Andtfolk, H. M. Miettinen and M. Jalkanen: Suppression of tumor cell growth by syndecan- 1 ectodomain. J Biol Chem, 269(45), 27795-8 (1994)
75. M. V. Dhodapkar, E. Abe, A. Theus, M. Lacy, J. K. Langford, B. Barlogie and R. D. Sanderson: Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood, 91(8), 2679-88 (1998)
76. E. J. Davies, F. H. Blackhall, J. H. Shanks, G. David, A. T. McGown, R. Swindell, R. J. Slade, P. Martin-Hirsch, J. T. Gallagher and G. C. Jayson: Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res, 10(15), 5178-86 (2004)
77. M. Barbareschi, P. Maisonneuve, D. Aldovini, M. G. Cangi, L. Pecciarini, F. Angelo Mauri, S. Veronese, O. Caffo, A. Lucenti, P. D. Palma, E. Galligioni and C. Doglioni: High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer, 98(3), 474-83 (2003)
78. J. R. Conejo, J. Kleeff, A. Koliopanos, K. Matsuda, Z. W. Zhu, H. Goecke, N. Bicheng, A. Zimmermann, M. Korc, H. Friess and M. W. Buchler: Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer, 88(1), 12-20 (2000)
79. Y. Hu, H. Sun, R. T. Owens, Z. Gu, J. Wu, Y. Q. Chen, J. T. O'Flaherty and I. J. Edwards: Syndecan-1- dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia, 12(10), 826-36 (2010)
80. C. Y. Pumphrey, A. M. Theus, S. Li, R. S. Parrish and R. D. Sanderson: Neoglycans, carbodiimidemodified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res, 62(13), 3722-8 (2002)
81. K. Ueda, S. Inoue, Y. Zhang, T. Kutsuna, K. Noto, N. Arai and M. Noguchi: Heparin induces apoptosis through suppression of AKt in oral squamous cell carcinoma cells. Anticancer Res, 29(4), 1079-88 (2009)
82. X. Chen, W. Xiao, X. Qu and S. Zhou: The effect of dalteparin, a kind of low molecular weight heparin, on lung adenocarcinoma A549 cell line in vitro. Cancer Invest, 26(7), 718-24 (2008)
83. G. Chatzinikolaou, D. Nikitovic, A. Berdiaki, A. Zafiropoulos, P. Katonis, N. K. Karamanos and G. N. Tzanakakis: Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling. Cell Prolif, 43(1), 9-18 (2010)
84. Y. Uzun, E. Akdogan, F. Ozdemir and E. Ovali: The effects of heparin on DLD-1 colon cancer cell line. Bratisl Lek Listy, 110(1), 3-6 (2009)
85. M. Balzarotti, F. Fontana, C. Marras, A. Boiardi, D. Croci, E. Ciusani and A. Salmaggi: In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res, 16(5), 245-50 (2006)
86. G. Kirfel, A. Rigort, B. Borm and V. Herzog: Cell migration: mechanisms of rear detachment and the formation of migration tracks. Eur J Cell Biol, 83(11-12), 717-24 (2004)
87. K. T. Chan, C. L. Cortesio and A. Huttenlocher: Integrins in cell migration. Methods Enzymol, 426, 47-67 (2007)
88. P. Friedl and K. Wolf: Proteolytic interstitial cell migration: a five-step process. Cancer Metastasis Rev, 28(1-2), 129-35 (2009)
89. K. Wolf and P. Friedl: Mapping proteolytic cancer cellextracellular matrix interfaces. Clin Exp Metastasis, 26(4), 289-98 (2009)
90. D. S. Micalizzi, S. M. Farabaugh and H. L. Ford: Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia, 15(2), 117-34 (2010)
91. D. A. Zajchowski, M. F. Bartholdi, Y. Gong, L. Webster, H. L. Liu, A. Munishkin, C. Beauheim, S. Harvey, S. P. Ethier and P. H. Johnson: Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res, 61(13), 5168-78 (2001)
92. H. Hugo, M. L. Ackland, T. Blick, M. G. Lawrence, J. A. Clements, E. D. Williams and E. W. Thompson: Epithelial - mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J Cell Physiol, 213(2), 374-83 (2007)
93. L. Tamagnone, S. Artigiani, H. Chen, Z. He, G. I. Ming, H. Song, A. Chedotal, M. L. Winberg, C. S. Goodman, M. Poo, M. Tessier-Lavigne and P. M. Comoglio: Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell, 99(1), 71-80 (1999)
94. R. Montesano, K. Matsumoto, T. Nakamura and L. Orci: Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell, 67(5), 901-8 (1991)
95. S. Barr, S. Thomson, E. Buck, S. Russo, F. Petti, I. Sujka-Kwok, A. Eyzaguirre, M. Rosenfeld-Franklin, N. W. Gibson, M. Miglarese, D. Epstein, K. K. Iwata and J. D. Haley: Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis, 25(6), 685-93 (2008)
96. G. Raab and M. Klagsbrun: Heparin-binding EGF-like growth factor. Biochim Biophys Acta, 1333(3), F179-99 (1997)
97. K. Itoh and S. Y. Sokol: Heparan sulfate proteoglycans are required for mesoderm formation in Xenopus embryos. Development, 120(9), 2703-11 (1994)
98. J. A. Deakin, B. S. Blaum, J. T. Gallagher, D. Uhrin and M. Lyon: The binding properties of minimal oligosaccharides reveal a common heparan sulfate/dermatan sulfate-binding site in hepatocyte growth factor/scatter factor that can accommodate a wide variety of sulfation patterns. J Biol Chem, 284(10), 6311-21 (2009)
99. K. R. Catlow, J. A. Deakin, Z. Wei, M. Delehedde, D. G. Fernig, E. Gherardi, J. T. Gallagher, M. S. Pavao and M. Lyon: Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density. J Biol Chem, 283(9), 5235-48 (2008)
100. K. Catlow, J. A. Deakin, M. Delehedde, D. G. Fernig, J. T. Gallagher, M. S. Pavao and M. Lyon: Hepatocyte growth factor/scatter factor and its interaction with heparan sulphate and dermatan sulphate. Biochem Soc Trans, 31(2), 352-3 (2003)
101. J. Villena and E. Brandan: Dermatan sulfate exerts an enhanced growth factor response on skeletal muscle satellite cell proliferation and migration. J Cell Physiol, 198(2), 169-78 (2004)
102. I. Vlodavsky, A. Eldor, A. Haimovitz-Friedman, Y. Matzner, R. Ishai-Michaeli, O. Lider, Y. Naparstek, I. R. Cohen and Z. Fuks: Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis, 12(2), 112-27 (1992)
103. X. Li and J. F. Wu: Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs). Recent Pat Anticancer Drug Discov, 5(2), 109-41 (2010)
104. E. Cohen, I. Doweck, I. Naroditsky, O. Ben-Izhak, R. Kremer, L. A. Best, I. Vlodavsky and N. Ilan: Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer, 113(5), 1004-11 (2008)
105. L. Fux, N. Feibish, V. Cohen-Kaplan, S. Gingis- Velitski, S. Feld, C. Geffen, I. Vlodavsky and N. Ilan: Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res, 69(5), 1758-67 (2009)
106. V. Cohen-Kaplan, I. Doweck, I. Naroditsky, I. Vlodavsky and N. Ilan: Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res, 68(24), 10077-85 (2008)
107. V. Cohen-Kaplan, I. Naroditsky, A. Zetser, N. Ilan, I. Vlodavsky and I. Doweck: Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer, 123(11), 2566-73 (2008)
108. T. M. Niers, C. P. Klerk, M. DiNisio, C. J. Van Noorden, H. R. Buller, P. H. Reitsma and D. J. Richel: Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol, 61(3), 195-207 (2007)
109. J. Gao, L. Su, R. Qin, Q. Chang, T. Huang and Y. Feng: Transfection of antisense oligodeoxynucleotide inhibits heparanase gene expression and invasive ability of human pancreatic cancer cell in vitro. J Huazhong Univ Sci Technolog Med Sci, 26(1), 72-4 (2006)
110. O. Goldshmidt, E. Zcharia, R. Abramovitch, S. Metzger, H. Aingorn, Y. Friedmann, V. Schirrmacher, E. Mitrani and I. Vlodavsky: Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc Natl Acad Sci U S A, 99(15), 10031-6 (2002)
111. M. Nakajima, A. DeChavigny, C. E. Johnson, J. Hamada, C. A. Stein and G. L. Nicolson: Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem, 266(15), 9661-6 (1991)
112. J. W. Dennis and S. Laferte: Tumor cell surface carbohydrate and the metastatic phenotype. Cancer Metastasis Rev, 5(3), 185-204 (1987)
113. S. Hakomori: Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Research, 56(23), 5309-18 (1996)
114. Y. S. Kim, J. Gum, Jr. and I. Brockhausen: Mucin glycoproteins in neoplasia. Glycoconj J, 13(5), 693-707 (1996)
115. R. Kannagi: Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J, 14(5), 577-84 (1997)
116. G. S. Kansas and F. M. Pavalko: The cytoplasmic domains of E- and P-selectin do not constitutively interact with alpha-actinin and are not essential for leukocyte adhesion. J Immunol, 157(1), 321-5 (1996)
117. L. R. Zacharski, W. G. Henderson, F. R. Rickles, W. B. Forman, C. J. Cornell, Jr., R. J. Forcier, R. L. Edwards, E. Headley, S. H. Kim, J. F. O'Donnell and et al.: Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75 . Cancer, 53(10), 2046-52 (1984)
118. H. Engelberg: Actions of heparin that may affect the malignant process. Cancer, 85(2), 257-72 (1999)
119. M. Hejna, M. Raderer and C. C. Zielinski: Inhibition of metastases by anticoagulants. J Natl Cancer Inst, 91(1), 22-36 (1999)
120. L. P. Fielding, R. Hittinger, R. H. Grace and J. S. Fry: Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet, 340(8818), 502-6 (1992)
121. B. Lebeau, C. Chastang, J. M. Brechot, F. Capron, B. Dautzenberg, C. Delaisements, M. Mornet, J. Brun, J. P. Hurdebourcq and E. Lemarie: Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer, 74(1), 38-45 (1994)
122. D. Nitti, J. Wils, T. Sahmoud, D. Curran, M. L. Couvreur, M. Lise, H. Rauschecker, J. G. dos Santos, W. Stremmel and F. Roelofsen: Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer, 33(8), 1209-15 (1997)
123. C. C. Zielinski and M. Hejna: Warfarin for cancer prevention. N Engl J Med, 342(26), 1991-3 (2000)
124. A. Koenig, K. Norgard-Sumnicht, R. Linhardt and A. Varki: Differential interactionsof heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest, 101(4), 877-89 (1998)
125. L. Wang, J. R. Brown, A. Varki and J. D. Esko: Heparin's anti-inflammatory effects require glucosamine 6- O-sulfation and are mediated by blockade of L- and Pselectins. J Clin Invest, 110(1), 127-36 (2002)
126. D. Y. Lee, K. Park, S. K. Kim, R. W. Park, I. C. Kwon, S. Y. Kim and Y. Byun: Antimetastatic effect of an orally active heparin derivative on experimentally induced metastasis. Clin Cancer Res, 14(9), 2841-9 (2008)
127. M. S. Pavao, K. R. Aiello, C. C. Werneck, L. C. Silva, A. P. Valente, B. Mulloy, N. S. Colwell, D. M. Tollefsen and P. A. Mourao: Highly sulfated dermatan sulfates from Ascidians. Structure versus anticoagulant activity of these glycosaminoglycans. J Biol Chem, 273(43), 27848-57 (1998)
128. R. J. Fonseca and P. A. Mourao: Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Thromb Haemost, 96(6), 822-9 (2006)
129. E. O. Kozlowski, M. S. G.; Borsig, L.: Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. Submitted (2011)
130. E. O. Kozlowski; Gomes, A. M.; Silva, C. F. S.; Pavão, M. S. G.: Structure and biological activities of glycosaminoglycan analogs from marine invertebrates: New therapeutic agents? In: Pavao, M.S.G. (ed) Glycans in therapeutics and disease, 1st edn. Springer, Heidelberg, In Press. (2011)
131. S. Alban: From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest, 35 Suppl 1, 12-20 (2005)
132. J. G. Martin, M. Gupta, Y. Xu, S. Akella, J. Liu, J. S. Dordick and R. J. Linhardt: Toward an artificial Golgi: redesigning the biological activities of heparan sulfate on a digital microfluidic chip. J Am Chem Soc, 131(31), 11041-8 (2009)